Phase III Arcadia 1 and 2 trial primary results published in The Lancet: Galderma’s nemolizumab improves key aspects of atopic dermatitis – itch, skin lesions and sleep disturbance Press release
Galderma granted key manufacturing license updates for new biologics capabilities at its center of excellence Press release
Galderma launches Restylane® Volyme™ in China – one of the world’s fastest growing aesthetics markets Press release
Galderma receives filing acceptances for nemolizumab in prurigo nodularis and atopic dermatitis in four additional countries Press release
Galderma prices IPO at CHF 53 per share and will start trading on the SIX Swiss Exchange tomorrow Press release
Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion Press release